We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+7.14%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$572M
AUM Growth
-$9.61M
Cap. Flow
-$82.5M
Cap. Flow %
-14.43%
Top 10 Hldgs %
86.44%
Holding
30
New
4
Increased
5
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$18M
2
OMED
OncoMed Pharmaceuticals, Inc.
OMED
+$12.8M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$12.5M
4
XNCR icon
Xencor
XNCR
+$7.03M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$5.73M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$27.6M
2
EXEL icon
Exelixis
EXEL
+$14.6M
3
ARRY
Array Biopharma Inc
ARRY
+$11.8M
4
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$10.3M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$7.03M

Sector Composition

Rank Sector Weight
1 Healthcare 76.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FLNA
26
Filana Therapeutics
FLNA
$48.3M
– –
-336,761
Closed -$6.41M
AVNR
27
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
– –
-2,436,053
Closed -$10.3M
GNVC
28
DELISTED
GenVec, Inc.
GNVC
– –
-48,610
Closed -$617K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2013 Portfolio in Review

As of Q4 2013, BVF Inc held 30 positions worth $572M, down 1.7% from $581M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

BVF Inc withdrew a net $82.5M in Q4 2013, closing 4 positions and reducing 6 holdings. Its most notable exit was Exelixis, an estimated $14.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 79% a quarter earlier.

Against the trend, BVF Inc opened a new position in Xencor worth $7.5M.

  • BVF Inc's largest Q4 2013 buy was Xencor: 820,000 shares worth $7.5M.
  • BVF Inc added most to Ironwood Pharmaceuticals in Q4 2013, an estimated $18M increase.
  • BVF Inc's biggest Q4 2013 reduction was Ligand Pharmaceuticals, cutting an estimated $27.6M.
  • BVF Inc fully exited Exelixis in Q4 2013, selling an estimated $14.6M.
  • BVF Inc's ten largest holdings make up 86% of its $572M portfolio in Q4 2013.
  • BVF Inc opened 4 new positions and closed 4 in Q4 2013.
  • BVF Inc's portfolio value fell 1.7% quarter-over-quarter to $572M.

Based on BVF Inc's 13F filing for Q4 2013, filed 14 Feb 2014.